Sumit Jamuar is the Chairman & CEO of Global Gene Corp. Mr. Jamuar brings rich expertise in creating, transforming and turning around businesses and is responsible for driving the long-term strategy, partnerships and overall vision at Global Gene Corp.

Previously, he has held several senior leadership positions in start-ups, global client coverage, strategy & transformation and a turnaround unit in an FTSE 100 company in London. Mr. Jamuar has also served as a Consultant with McKinsey & Company, India.

Earlier in his career, Mr. Jamuar served as Managing Director & Global Head in the Financial Institutions team at Lloyds Corporate Bank, London where he was responsible for the global business looking after banks, fund managers, insurance companies, group subsidiaries, relevant public entities and specialist finance. He has been an Advisor to GEMS Education, the award winning K-12 private education provider, for their expansion in Africa.

Mr. Jamuar serves as the Co-Chair of the United Nations ITU - Gates foundation initiative for financial inclusion.

Mr. Jamuar holds a bachelor’s degree in Chemical Engineering from Indian Institute of Technology, Delhi, and an MBA from INSEAD, Fontainebleau. He is a Fellow of the Institute of Directors, London.

Dr. Jonathan Picker is a co-founder of Global Gene Corp. He is a faculty member at Harvard Medical School and a clinical geneticist at Boston's Children's Hospital.

With 25 years of experience in Paediatrics and Genetics, Dr. Picker specialises in the interface of clinical care, applied research and education. This is reflected in his academic position at Harvard Medical School as an Assistant Professor in clinical expertise with special interest in research in the department of Paediatrics. Dr. Picker's research spans diagnostic tools in genetics to descriptive analysis of rare disorders to molecular neuroscience.

Dr. Picker's primary focus has been on the genetics underlying intellect and behaviour. He has developed a number of innovative programs and web-based tools to assist primary care practitioners and their patients to understand and use the knowledge of rare disorders to significantly improve care. He also developed new-born screening protocols for inborn errors of metabolism for the New England Consortium of metabolic programs that were used as templates. Notably, the NIH developed the national "ACT sheet" guidelines for paediatricians throughout the US on the basis of these protocols. This experience was consequently utilised by Dr. Picker when he was chosen to chair the National Fragile X Clinic and Research Consortium’s clinical committee to lead the development of accessible guidelines to help both physicians and families with a wide range of complex issues.

Dr. Picker continues to be involved in research and clinical care and is the Director of Harvard's fragile X program at Boston Children's Hospital. He is a member of the American Society of Human Genetics, American Academy of Child & Adolescent Psychiatry, New England Council of Child Psychiatry and New England Regional Genetics Group.

A recipient of various prestigious awards, Dr. Picker’s honours include the Sidney R. Baer Jr. Prize for Mental health Research (first recipient) in 2005, Research Award by HealthEmotions Research Institute, University of Wisconsin in 2003, Warren Dupont Fellowship award and Children’s Hospital, Boston Developmental Medicine Research Fellowship Award in 2002. He was also honoured with the Society for Inborn errors of Metabolism (SIMD) Research award in 2001 and the John Hunter Award for academic excellence in Medical School from 1985 to 1987.

He has authored numerous research papers involving informative cases, molecular biology, behavioural neuroscience and practical online clinical guidelines. More recently he has focused on applying his knowledge to diagnostics with a view towards developing more pragmatic genetic tests that take the field from the esoteric to the practical world of medicine.

Dr. Picker holds a bachelors degree of Medical Biology (commend.) in Genetics, and an MBChB in Medicine from Aberdeen University, UK. He also holds an MS in Genetics and Biochemistry and a PhD in Molecular Biology from Newcastle University, UK.

Dr. Saumya Jamuar is a co-founder of Global Gene Corp and currently a Visiting Scientist at Harvard Medical School, US.

Dr. Jamuar strongly believes in using the advancements made in technologies related to genetics to improve the health of people. His strong training in paediatrics allows him to appreciate the severity of rare but lethal childhood illnesses and, more importantly, recognise the fact that a significant proportion of these illnesses have a genetic component. In his desire to improve care across the health industry, he is actively involved in developing diagnostic genetic tests for patients with various medical disorders, including autism spectrum disorder, intellectual disability, and brain malformations.

Dr. Jamuar has a broad range of research interests and has published several reports and made presentations at international meetings on inherited genetic diseases such as hemoglobinopathy, inherited metabolic diseases and chromosomal disorders. He is currently involved in understanding the genetics of human brain development and has in-depth knowledge of cutting-edge genetic technologies, such as whole genome sequencing, RNA sequencing, and microarrays.

He is a member of the American Society of Human Genetics, American College of Medical Genetics, Society of Inherited Metabolic Disorders and Singapore Medical Society.

Dr. Jamuar holds an MBBS in Medicine from National University of Singapore. He also holds a Membership of the Royal College of Paediatric and Child Health (M.R.C.P.C.H), UK, and a Fellowship of Academy of Medicine (F.A.M.S), Singapore. He has completed his Clinical Genetics training from the Harvard Medical School Genetics Training Program.

Kushagra Sharma is the Chief Operating Officer at Global Gene Corp. A seasoned business leader with a career spanning entrepreneurship as well as general management, Mr. Sharma has deep expertise in developing and executing business plans in start-ups as well as large corporations. He is responsible for managing the day-to-day operations and revenue growth of the business, strategic planning, partnerships and service delivery at Global Gene Corp.

Before joining Global Gene Corp, he was responsible for the strategy and project execution in launching 4G digital services for Reliance Jio Infocomm in India. He was a key member of the core team responsible for strategic planning, key partnerships and project execution of the USD10 billion project. With his eye for detail and operational expertise, he has been instrumental in building companies to scale in India as well as in the UK.

Mr. Sharma holds a bachelor's degree from Indian Institute of Technology, Delhi and an MBA from INSEAD, Fontainebleau.

Dr. Yaron Turpaz is a proven research and development Informatics, data sciences and technology leader in the biotech and pharma space with hands on experience using cloud based high throughput computational and genomics platforms for drug discovery and development applications in precision medicine.

As Chief Data & Technology Officer at Global Gene Corp., and Managing Director of GGC Singapore, Dr. Turpaz is responsible for the enhancement and development of the company's global data and technology infrastructure, advance analytics, data sciences and machine learning, as well as the expansion of GGC’s Asia operations at Singapore.

Dr. Turpaz was previously the Chief Information Officer at Human Longevity, Inc. (HLI), where he was responsible for building and growing the company’s awards winning AWS based genomic and phenotypic Knowledgebase^TM business, and led all bioinformatics/informatics and software engineering efforts, including the launch of the Health Nucleus App and the Medical Avatar that integrates client’s health data with genomics, imaging, metabolome and microbiome metagenome analysis. He expanded the global informatics program at HLI and established teams at San Diego, CA and Singapore, with a focus on collaborations and business development with the pharmaceutical, healthcare and insurance industries. Driving the expansion to Asia, Dr. Turpaz also functioned as the Managing Director of Human Longevity Singapore. Prior to joining HLI, he worked at AstraZeneca as Vice President, R&D IT. In this position he led a global team of approximately 300 and was accountable for the more than $120 million R&D IT budget, leading the development of Big Data analytics, knowledge engineering, real world evidence and scientific informatics solutions across the company’s drug discovery & development pipeline for a variety of therapeutic areas including oncology, diabetes, cardiovascular, neuroscience and infectious diseases. Before AZ, Dr. Turpaz joined the establishment of Eli Lilly Singapore Centre for Drug Discovery as Director of Integrative Computational Sciences, towards in-silico acceleration of drug discovery and biomarker identification for oncology and metabolic diseases. While there, he co-established the Asian Cancer Research Group (ACRG) in collaboration with Merck and Pfizer. The ACRG is a not-for-profit organization conducting genomic and proteomic analysis on cancers prevalent in Asian populations. Prior to joining Lilly, Dr. Turpaz was a Senior Manager, Bioinformatics and Algorithms Development at Affymetrix, Inc. There he managed a team of bioinformaticians, statisticians and software engineers who developed informatics solutions for a variety of GeneChip^TM microarray applications. He and his team were contributing to the development and launch of six successful commercial microarray products there.

Dr. Turpaz has a BS in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School.

Shalendra Porwal is the President – Institutional Sales at Global Gene Corp. A research and technology expert, Mr. Porwal brings extensive expertise and experience in institutional sales and applying & commercializing intellectual property (IP). He has broad knowledge of diverse technological areas and is adept in the business and financial aspects of setting up and growing businesses. His knowledge of science and technology, business and political climates, business rules and regulations, tax incentives for R&D, and bureaucracy in India and the U.S. is admirable. He also has extensive experience in B2B business development spanning consumer goods to industrial products. At Global Gene Corp, he is responsible for protecting, marketing and commercializing intellectual property working alongside the in-house R&D team.

Before joining Global Gene Corp, he held several leadership positions in US and India. In the past, he has worked with Battelle India as its Managing Director and CEO. Here, he led the international business development and marketing with institutional clients for technology and IP. He also led over 100 applied R&D projects with 30 international industrial organizations. Earlier, he founded Technology Solutions International in Ohio and served as its CEO.

Mr. Porwal co-chairs the Science, Technology and Innovation committee of the Federation of Indian Chambers of Commerce and Industry (FICCI). He has also served as a Research Fellow at Champion Papers in Ohio and as a Scientific Officer at the Bhabha Atomic Research Center (BARC) in India. He has been a speaker at several R&D and innovation conferences both within India and USA.

Mr. Porwal holds an MBA and a Master’s degree in Paper Science and Technology from Miami University and a Bachelor’s degree in Chemical Engineering from Indian Institute of Technology, Kharagpur.